Included in the formulation
АТХ:G.02.A.B Preparations of ergot alkaloids
G.02.A.B.01 Methylergometrine
Pharmacodynamics:Stimulates α-adrenoreceptors, increases the tone of the myometrium, due to this, muscle fibers compress the vessels of the uterine wall. Narrowing of peripheral vessels. Stimulates the centers of the vagus nerve and the trigger zone of the vomiting center, depresses the vasomotor center. Has a sedative effect. Slightly increases blood pressure.It inhibits the production of prolactin and the secretion of milk.
Pharmacokinetics:After oral administration, fasted to 60% is absorbed in the gastrointestinal tract and absorbed in an amount of 78% after intramuscular injection. The maximum concentration in the blood plasma is reached after 30 minutes. The therapeutic effect develops 30 seconds after intravenous injection, 2-5 minutes after intramuscular injection and 5-10 minutes after ingestion. Metabolism in the liver.
The half-life is 32 minutes. Elimination by the kidneys in the form of metabolites (95%).
With repeated administration does not cumulate. The duration of action is 4-6 hours.
Indications:It is used in the second stage of childbirth (after head eruption) for the prevention of postpartum hemorrhage, for the treatment of hypotonic and atonic bleeding, with metrorrhagia,to accelerate the subinvolution of the uterus, after gynecological operations, the lychiometer.
XIV.N80-N98.N85.3 Subinvolution of the uterus
XV.O60-O75.O67 Childbirth and delivery, complicated by bleeding during labor, not elsewhere classified
XV.O60-O75.O72.2 Later or secondary postpartum hemorrhage
XV.O60-O75.O72.1 Other bleeding in the early postpartum period
XV.O80-O84.O82 Singleton births, delivery was by caesarean section
XV.O85-O92.O90.8 Other complications of the postpartum period, not elsewhere classified
Contraindications:I and II (before the eruption of the fetal head) periods of labor, obliterating vascular diseases, individual intolerance of ergot preparations.
Carefully:Ischemic heart disease, hepatic and renal failure, stenosis of the mitral valve.
Pregnancy and lactation:Recommendations for FDA - not determined. Contraindicated during pregnancy, can have a depressing effect on lactation.
Dosing and Administration:Intravenously or intramuscularly 0.2 mg every 2-4 hours, up to 5 injections. Inside or subcutaneously 0.1 mg or intramuscularly 0.2 mg 3 times / day.
The highest daily dose: 1 mg.
The highest single dose: 0.2 mg.
Side effects:Central and peripheral nervous system: headache, dizziness.
The cardiovascular system: increased arterial pressure, arrhythmia, spasm of peripheral vessels.
Dermatological manifestations: hyperhidrosis, rash.
Reproductive system: hypogalactia.
Allergic reactions.
Overdose:Symtomas: stenocardia, miosis, confusion, numbness of hands or feet, weak pulse, respiratory depression, thirst, tetany of the uterus.
Treatment: symptomatic.
Interaction:Strengthens the vasoconstrictive effects of sympathomimetics.
With simultaneous application with oxytocin, the development of hypertensive crisis is possible.
Special instructions:Ineffective as an abortifacient. In the absence of an instant reaction after intravenous injection, it is recommended to administer calcium preparations restoring sensitivity to methylergometrin.